Search

Soileau, MJ, J Aldred, K Budur, N Fisseha, VS Fung, A Jeong, TE Kimber, et al. 2022. “Safety and Efficacy of Continuous Subcutaneous Foslevodopa-Foscarbidopa in Patients With Advanced Parkinson’s Disease: a Randomised, Double-Blind, Active-Controlled, Phase 3 Trial. 2022 Dec;21(12):1099-1109. Doi: 10. PMID: 36402160”. Lancet Neurol.

Simuni, T, B Fiske, K Merchant, CS Coffey, E Klingner, C Caspell-Garcia, DE Lafontant, et al. 2021. “Parkinson Study Group NILO-PD Investigators and Collaborators (including Hauser RA). Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol 2021;78:312-320.”. JAMA Neurol.

Doiron, Jake E, Mahmoud H Elbatreek, Huijing Xia, Xiaoman Yu, W H Wilson Tang, Kyle B LaPenna, Thomas E Sharp, et al. 2024. “Reduced Hydrogen Sulfide Bioavailability Contributes to Cardiometabolic Heart Failure With Preserved Ejection Fraction.”. BioRxiv : The Preprint Server for Biology.

Naito, A, AM Wills, TF Tropea, A Ramirez-Zamora, RA Hauser, D Martino, TH Turner, and . 2021. “Expediting Telehealth Use in Clinical Research Studies: Recommendations for Overcoming Barriers in North America. NPJ Parkinsons Dis 2021;7:34. Doi: 10.1038/S41531-021-00177-8.PMID: 33846349”. NP J Parkinsons Dis.

Mehta, SH, R Pahwa, CM Tanner, RA Hauser, and R Johnson. 2021. “Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients With Parkinson’s Disease and Dyskinesia. Neurol Ther. 2021 Jun;10(1):307-320. Doi: 10.1007/S40120-021-00246-3”. Neurol Ther.

Videnovic, A, AW Amara, C Comella, PK Schweitzer, H Emsellem, K Liu, AL Sterkel, et al. 2021. “Solriamfetol for Excessive Daytime Sleepiness in Parkinson’s Disease: Phase 2 Proof-of-Concept Trial. Mov Disord. 2021 Oct;36(10):2408-2412. Doi: 10.1002/Mds.28702. Epub 2021 Jun 30. PMID: 34191352.”. Mov Disord.

Hauser, RA, Parkinsons Study Group SURE-PD3 Investigators, and . 2021. “Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3.Randomized Clinical Trial. JAMA. 2021 Sep 14;326(10):926-939. Doi: 0.1001/Jama.2021.10207. PMID: 34519802.”. JAMA.

“Cenci MA, Riggare S, Pahwa R, Eidelberg D, Hauser RA. Dyskinesia Matters. Mov Disord 2020;35:392-396.”. 2020. Mov Disord.

Hauser, RA, L Zeitlin, S Fisher, and R D’Souza. 2020. “Carbidopa and Levodopa Extended Release Capsules (Rytary®) in Patients With and Without Troublesome and Non-Troublesome Dyskinesia. J Parkinsons Dis 2020;10:915-925.”. J Parkinsons Dis.

Valdes, EG, ML O’Connor, EY Uc, RA Hauser, R Andel, and JD Edwards. 2017. “Use, Maintenance and Dose Effects of Cognitive Speed of Processing Training in Parkinson’s Disease. Int J Neurosci 2017;127:841-848.”. Int J Neurosci.